Analyst Downgrades AstraZeneca Stock Due to Vaccine Side Effect Concerns

Cory Renauer, The Motley Fool
·2-min read
Analyst Downgrades AstraZeneca Stock Due to Vaccine Side Effect Concerns

The odds of experiencing a fatal blood clot following inoculation with AstraZeneca's COVID-19 vaccine are less than one in a million, but that was enough to spook Argus Research.